memantine hydrochloride

×

Overview

What is memantine hydrochloride?

Memantine hydrochloride is an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula:

The molecular formula is CHN•HCl and the molecular weight is 215.76. Memantine HCl occurs as a fine white to off-white powder and is soluble in water.

Memantine HCl is available as tablets or as an oral solution. Memantine HCl is available for oral administration as capsule-shaped, film-coated tablets containing 5 mg and 10 mg of memantine hydrochloride. The tablets also contain the following inactive ingredients: microcrystalline cellulose/colloidal silicon dioxide, talc, croscarmellose sodium, and magnesium stearate. In addition the following inactive ingredients are also present as components of the film coat: hypromellose, titanium dioxide, polyethylene glycol 400, FD&C yellow #6 and FD&C blue #2 (5 mg tablets), and hypromellose, titanium dioxide, macrogol/polyethylene glycol 400 and iron oxide black (10 mg tablets). Memantine HCl oral solution contains memantine hydrochloride in a strength equivalent to 2 mg of memantine hydrochloride in each mL. The oral solution also contains the following inactive ingredients: sorbitol solution (70%), methylparaben, propylparaben, propylene glycol, glycerin, natural peppermint flavor #104, citric acid, sodium citrate, and purified water.

What does memantine hydrochloride look like?

What are the available doses of memantine hydrochloride?

Memantine HCl 5 mg tablet: capsule-shaped, film-coated tablets are tan, with the strength (5) debossed on one side and FL on the other.

Memantine HCl 10 mg tablet: capsule-shaped, film-coated tablets are gray, with the strength (10) debossed on one side and FL on the other.

Memantine HCl 2 mg/mL oral solution: clear, alcohol-free, sugar-free, and peppermint flavored.

What should I talk to my health care provider before I take memantine hydrochloride?

How should I use memantine hydrochloride?

Memantine hydrochloride is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

The recommended starting dose of Memantine HCl is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.

Memantine HCl can be taken with or without food. If a patient misses a single dose of Memantine HCl, that patient should not double up on the next dose. The next dose should be taken as scheduled.

If a patient fails to take Memantine HCl for several days, dosing may need to be resumed at lower doses and retitrated as described above.

Do not mix Memantine HCl oral solution with any other liquid. The oral solution is administered with a dosing device that comes with the drug and consists of a syringe, syringe adaptor cap, tubing and other supplies a patient needs to administer the drug. The supplied syringe should be used to withdraw the correct volume of oral solution and the oral solution should be slowly squirted into the corner of the patient's mouth.

What interacts with memantine hydrochloride?

Sorry No Records found

What are the warnings of memantine hydrochloride?

Sorry No Records found

What are the precautions of memantine hydrochloride?

Sorry No Records found

What are the side effects of memantine hydrochloride?

Sorry No records found

What should I look out for while using memantine hydrochloride?

Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

What might happen if I take too much memantine hydrochloride?

Signs and symptoms most often accompanying memantine overdosage in clinical trials and from worldwide marketing experience, alone or in combination with other drugs and/or alcohol, include agitation, asthenia, bradycardia, confusion, coma, dizziness, ECG changes, increased blood pressure, lethargy, loss of consciousness, psychosis, restlessness, slowed movement, somnolence, stupor, unsteady gait, visual hallucinations, vertigo, vomiting, and weakness. The largest known ingestion of memantine worldwide was 2.0 grams in a patient who took memantine in conjunction with unspecified antidiabetic medications. The patient experienced coma, diplopia, and agitation, but subsequently recovered. Fatal outcome has been very rarely reported with memantine, and the relationship to memantine was unclear.

Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center to determine the latest recommendations for the management of an overdose of any drug. As in any cases of overdose, general supportive measures should be utilized, and treatment should be symptomatic. Elimination of memantine can be enhanced by acidification of urine.

How should I store and handle memantine hydrochloride?

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 5 mg Tablet: Tan, capsule-shaped, film-coated tablets with “5” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3870-6010 x 10 Unit Dose NDC #0591-3870-44 10 mg Tablet: Gray, capsule-shaped, film-coated tablets with “10” debossed on one side and FL on the other. Bottle of 60 NDC #0591-3875-6010 x 10 Unit Dose NDC #0591-3875-44 Titration Pack: NDC #0591-3900-87Blister package containing 49 tablets (28 x 5 mg and 21 x 10 mg tablets). Oral Solution: 2 mg/mL Oral Solution (10 mg = 5 mL)12 fl. oz. (360 mL) bottle NDC #0591-3011-07 Store Memantine HCl tablets and oral solution at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease.

Non-Clinical Toxicology

Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.

Calcium channel blockers may also have an additive effect when given with atenolol (see ).

Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers.

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers.

Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta blockers.

Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.

While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: